Related Experiment Video
Updated: Aug 19, 2026

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Tiapamil--a new calcium antagonist
Abstract:
Calcium antagonists are an important new modality in cardiovascular therapy. Tiapamil, a congener of verapamil, is undergoing clinical and laboratory evaluation. We have undertaken experimental studies on the anti-arrhythmic properties of tiapamil, and on the intravenous use of this agent in patients with acute myocardial infarction. Reasons are given for suggesting that tiapamil warrants further clinical evaluation, after which it may join the more established calcium antagonists as a valuable therapeutic agent.
Insights
Tiapamil, a new calcium antagonist, shows promise for treating heart rhythm disorders and acute myocardial infarction. Further clinical studies are recommended to establish its therapeutic value alongside existing treatments.
Area of Science:
- Cardiovascular pharmacology
- Clinical electrocardiology
Background:
- Calcium antagonists represent a significant advancement in cardiovascular medicine.
- Tiapamil, a verapamil congener, is under investigation for its therapeutic potential.
Purpose of the Study:
- To evaluate the anti-arrhythmic effects of tiapamil.
- To assess the intravenous use of tiapamil in acute myocardial infarction patients.
Main Methods:
- Experimental studies on anti-arrhythmic properties.
- Clinical evaluation in patients with acute myocardial infarction.
Main Results:
- Preliminary experimental data suggest anti-arrhythmic properties.
- Intravenous administration in acute myocardial infarction warrants further investigation.
Conclusions:
- Tiapamil demonstrates potential as a novel cardiovascular therapeutic agent.
- Further clinical evaluation is necessary to confirm its role in established calcium antagonist therapy.
More Related Videos
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...